Casper Pharmaceuticals

Executive Summary

Casper Pharmaceuticals is a private, emerging specialty pharmaceutical company headquartered in Princeton, New Jersey. Founded in 2018, the company focuses on developing, acquiring, and commercializing therapies across cardiovascular, gastrointestinal, urological, pain management, and ophthalmic markets. By leveraging a global network, Casper aims to address unmet medical needs through a combination of in-house development and strategic acquisitions. Despite being early-stage, the company has positioned itself in diverse therapeutic areas with significant market potential, though it currently lacks disclosed pipeline details or approved commercial products. As a private entity with no publicly traded securities, Casper's progress is not widely tracked by analysts. The company's success hinges on its ability to execute acquisition strategies and advance proprietary programs toward clinical milestones. Given the lack of specific pipeline information, conviction in near-term value creation is moderate. Key upcoming catalysts would likely involve announcements of licensing deals, FDA interactions, or financing rounds to support R&D. Investors should monitor the company's website and industry conferences for updates on its evolving pipeline and business development activities.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a new licensing or acquisition agreement for a late-stage asset40% success
• Q2 2027FDA acceptance of an Investigational New Drug (IND) application for a lead candidate30% success
• Q1 2027Series B funding round to support pipeline advancement50% success